Orris

Gullien barre syndrome

Reading File
Finding Sources
Searching PubMed

"Guillain-Barre syndrome" AND treatment

Searching Images

Guillain-Barre syndrome demyelination nerve

Reading File
Reading File
Reading File

Guillain-Barré Syndrome (GBS)

Overview GBS is an acute, immune-mediated polyradiculoneuropathy and the most common cause of acute flaccid paralysis in the developed world since the near-eradication of polio. Mean annual incidence is about 1.8 per 100,000, rising with age (0.8/100,000 under 18 years to 3.2/100,000 over 60), with a male predominance (~1.5:1) - Bradley and Daroff's Neurology in Clinical Practice.
Pathophysiology About two-thirds of cases are triggered by an antecedent infection (most commonly 1-3 weeks prior) that provokes microbe-specific T cells and antibodies which cross-react with peripheral nerve antigens ("molecular mimicry"). Implicated organisms include Campylobacter jejuni, Epstein-Barr virus, cytomegalovirus, HIV, Zika virus, and SARS-CoV-2. Both T-cell- and antibody-mediated mechanisms contribute, with T cells thought to play the dominant role. Injury is most extensive at the nerve roots and proximal nerve segments, with macrophage-rich mononuclear infiltrates causing multifocal demyelination (or, in axonal variants, direct axonal injury) - Robbins & Kumar Basic Pathology; Bradley and Daroff's Neurology.
Clinical features
  • Fairly symmetric, ascending limb weakness that progresses over hours to days (maximum 4 weeks), often with distal paresthesias worse in the hands/fingers
  • Hyporeflexia/areflexia - an invariable feature, though it may be absent very early
  • Cranial nerve involvement in 45-75% (bilateral facial palsy most common)
  • Sensory loss is usually mild, typically limited to distal vibration sense; but moderate-severe back/limb pain occurs in ~70% during the acute phase and can persist for up to a year in a third of patients
  • Autonomic dysfunction (blood pressure lability, arrhythmias, ileus, bladder dysfunction)
  • Respiratory muscle involvement requiring ventilatory support in 9-30% of hospitalized cases, more common with increasing age
Subtypes/variants (Box 106.11, Bradley and Daroff's Neurology):
  • Common: Acute inflammatory demyelinating polyradiculoneuropathy (AIDP, most common in Europe/North America), Acute motor axonal neuropathy (AMAN, summer epidemics in children/young adults in northern China), Acute motor-sensory axonal neuropathy (AMSAN, involves both motor and sensory fibers, more severe with poorer recovery)
  • Rare: Miller-Fisher syndrome (ophthalmoplegia, ataxia, areflexia - ~6% of Western cases, up to 18% in Taiwan), acute ataxic neuropathy, pharyngeal-cervical-brachial variant, multiple cranial neuropathy variant, facial diplegia with paresthesias, paraparetic variant, acute pandysautonomia
Diagnosis (Ashbury & Cornblath criteria):
  • Required: progressive weakness of both legs and arms; areflexia/hyporeflexia
  • Supportive clinical features: progression over days to 4 weeks, relative symmetry, mild sensory signs, bifacial palsies, autonomic dysfunction, absence of fever at onset, recovery beginning 2-4 weeks after progression stops
  • Supportive lab features: elevated CSF protein with <10 cells/µL (albuminocytologic dissociation); electrodiagnostic evidence of conduction slowing/block
Treatment
  • Plasmapheresis (plasma exchange) to remove pathogenic antibodies
  • Intravenous immunoglobulin (IVIG) - immunomodulatory mechanism not fully defined
  • Supportive care, including close monitoring of respiratory and autonomic function and mechanical ventilation when needed
  • Corticosteroids are not effective and are not recommended
Prognosis Improvements in critical care (especially positive-pressure ventilation) have reduced mortality from ~33% historically to roughly 1-5% currently. Most patients who survive the acute phase recover over time, though residual pain, weakness, or fatigue can persist for months to years in a subset.
Recent evidence note: A 2025 systematic review/individual participant data meta-analysis (PMID: 41323217) examined GBS occurring after CAR T-cell therapy, and a 2025 systematic review (PMID: 40897982) described GBS and related neuropathies following bariatric surgery - both represent newer, less common trigger contexts not covered in standard textbooks. A 2024 systematic review (PMID: 38553651) looked at IVIG retreatment in patients with poor response to an initial cycle, which is relevant if considering re-dosing strategy but doesn't change first-line management above. These don't contradict the core textbook management principles but reflect ongoing refinement of etiology/subgroup management - worth deeper review if the question involves one of those specific triggers.
If you want, I can go deeper into a specific aspect - e.g. Miller-Fisher syndrome, differentiating GBS from other acute weakness syndromes, or ICU/ventilatory management specifics.
This is a shared conversation. Sign in to Orris to start your own chat.